Summary
EudraCT Number: 2009-009369-32
Sponsor's Protocol Code Number: ENB-003-08
National Competent Authority: UK - MHRA 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2009-04-14
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-009369-32/GB/

A. Protocol Information
A.1 Member State Concerned: UK - MHRA
A.2 EudraCT number: 2009-009369-32
A.3 Full title of the trial: Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children with Hypophosphatasia (HPP)
A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language: Extension open-label use of ENB-0040 for infantile hypophosphatasia
A.4.1 Sponsor's protocol code number: ENB-003-08
A.7 Trial is part of a Paediatric Investigation Plan: Yes
A.8 EMA Decision number of Paediatric Investigation Plan: P/176/2014

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Alexion Pharma GmbH
B.1.3.4	Country: Switzerland
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support: Alexion Pharma GmbH
B.4.2 Country: Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: ALEXION EUROPE SAS
B.5.2 Functional name of contact point: European Clinical Trial Information
B.5.3 Address
B.5.3.1 Street Address: 1-15 avenue Edouard Belin
B.5.3.2 Town/ city: Rueil-Malmaison
B.5.3.3 Post code: 92500
B.5.3.4 Country: France
B.5.4 Telephone number: +33147100606
B.5.5 Fax number: +33147100611
B.5.6 E-mail: clinicaltrials.eu@alexion.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: Strensiq
D.2.1.1.2 Name of the Marketing Authorisation holder: Alexion Europe SAS
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: Yes
D.2.5.1 Orphan drug designation number: EU/3/08/594
D.3 Description of the IMP
D.3.1 Product name: Asfotase alfa
D.3.2 Product code: Asfotase alfa
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Asfotase alfa
D.3.9.2 Current sponsor code: Asfotase alfa
D.3.9.3 Other descriptive name: Human recombinant tissue non-specific alkaline phosphatase fusion protein
D.3.10 Strength
D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 40 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Infantile hypoposphatasia
E.1.1.1 Medical condition in easily understood language: Hypophosphatasia, a bone disorder caused by gene mutations or changes. These gene mutations result in low levels of an enzyme needed to harden bones.
E.1.1.2 Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 19.1
E.1.2 Level: PT
E.1.2 Classification code: 10049933
E.1.2 Term: Hypophosphatasia
E.1.2 System Organ Class: 10010331 - Congenital, familial and genetic disorders
E.1.3 Condition being studied is a rare disease: Yes
E.2 Objective of the trial
E.2.1 Main objective of the trial: - To determine the long-term tolerability of subcutaneous (SC) Asfotase alfa
- To assess the long-term efficacy of Asfotase alfa in treating rickets in infants and young children with HPP
E.2.2 Secondary objectives of the trial: - To assess the long-term pharmacodynamics (PD) of SC Asfotase alfa
- To assess the effect of SC Asfotase alfa on growth and development
- To assess the effect of SC Asfotase alfa on mortality and other clinical signs and symptoms of HPP in infants and young children
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: · Compliant and satisfactory completion, in the opinion of the Sponsor and Investigator, of study
ENB-002-08
· Written informed consent by parent or other legal guardian prior to any study procedures being
performed
· Parent or other legal guardian willing to comply with study requirements
E.4 Principal exclusion criteria: - The patient has a history of sensitivity to any ENB 0040 constituents
- The patient has a clinically significant disease that precludes study participation, in the Investigator’s opinion
- The patient has been enrolled in any study involving an investigational drug, device, or treatment for HPP (e.g., one marrow transplantation)

E.5 End points
E.5.1 Primary end point(s): Skeletal radiograph using a qualitative Radiographic Global Impression of Change (RGI-C) scale.

E.5.1.1 Timepoint(s) of evaluation of this end point: 84 months
E.5.2 Secondary end point(s): Long-term pharmacodynamics of SC Asfotase alfa.
Effect of SC Asfotase alfa on growth and development, mortality, and other clinical signs and symptoms of HPP in infants and young children.
E.5.2.1 Timepoint(s) of evaluation of this end point: 84 months
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: Information not present in EudraCT
E.8.1.2 Open: Yes
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Information not present in EudraCT
E.8.2.2 Placebo: Information not present in EudraCT
E.8.2.3 Other: Information not present in EudraCT
E.8.2.4 Number of treatment arms in the trial: 1
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 2
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: No
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
United Arab Emirates
United States
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Database Lock
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 4
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 4
E.8.9.2 In all countries concerned by the trial months: 0
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1 Number of subjects for this age range: 6
F.1.1.1 In Utero: No
F.1.1.1.1 Number of subjects for this age range: 0
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.2.1 Number of subjects for this age range: 0
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): Yes
F.1.1.4.1 Number of subjects for this age range: 5
F.1.1.5 Children (2-11years): Yes
F.1.1.5.1 Number of subjects for this age range: 5
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: This study will enrol infants and young children
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 5
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 5
F.4.2.2 In the whole clinical trial: 10
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Expected normal treatment

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2009-03-12
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2009-03-30

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2017-02-07

